Last updated: September 7, 2026
Afrezza is a niche inhaled insulin product marketed by MannKind Corporation in the United States. Its commercial value depends on expanding adoption among insulin-using adults who want to avoid mealtime injections, while its financial profile is constrained by limited market share, reimbursement friction, pulmonary monitoring requirements, and competition from rapid-acting injectable insulin, insulin pumps, and newer diabetes therapies.
MannKind’s broader financial growth has increasingly come from its Technosphere inhalation platform and manufacturing agreements, particularly its relationship with United Therapeutics. Afrezza remains strategically important, but it is no longer the company’s only material growth driver.
What is Afrezza and how does its delivery system work?
Afrezza is a dry-powder formulation of recombinant human insulin delivered through an inhaler. MannKind’s Technosphere technology uses fumaryl diketopiperazine particles to transport insulin into the deep lung, where it is absorbed rapidly.
The FDA approved Afrezza in June 2014 under New Drug Application 022472. The product is indicated for improving glycemic control in adults with diabetes mellitus. It is a mealtime insulin and does not replace long-acting basal insulin in patients with type 1 diabetes.[1]
Afrezza has several technical characteristics that differentiate it from injectable insulin:
| Attribute |
Afrezza |
| Active ingredient |
Recombinant human insulin |
| Delivery route |
Oral inhalation into the lungs |
| Dosage form |
Single-use inhalation cartridges |
| Main use |
Mealtime glucose control |
| Basal insulin replacement |
No |
| FDA pathway |
NDA approval |
| Primary commercial company |
MannKind |
| Principal technology |
Technosphere inhalation platform |
The product is sold in 4-, 8-, and 12-unit cartridges. Dose conversion is not directly equivalent to injectable insulin units, which creates a training and prescribing barrier. Afrezza also requires pulmonary assessment because of the risk of acute bronchospasm and reductions in pulmonary function.[1]
How large is the market for inhaled insulin?
The addressable market is large in absolute terms but narrow for Afrezza because inhaled insulin is a specialized delivery category.
The global insulin market includes basal insulin, rapid-acting insulin, premixed products, insulin pumps, and connected delivery systems. The largest commercial products are injectable biologics from Novo Nordisk, Eli Lilly, and Sanofi. Afrezza competes primarily in mealtime insulin rather than across the entire insulin market.
Its principal commercial target is adults with type 2 diabetes who:
- require prandial insulin;
- resist or delay injectable therapy;
- have difficulty with multiple daily injections;
- prefer a needle-free mealtime option; or
- need a rapid-onset insulin with short duration.
Afrezza is less competitive for patients who require precise pump-based dosing, continuous glucose management, or a basal-bolus regimen built around established injectable analogs.
Which products compete with Afrezza?
Afrezza competes with rapid-acting injectable insulins and diabetes technologies rather than with one direct inhaled-insulin rival.
| Competitive category |
Representative products or companies |
Commercial effect on Afrezza |
| Rapid-acting insulin analogs |
Humalog, Lyumjev, NovoLog, Fiasp, Apidra |
Established prescribing and reimbursement |
| Basal insulin combinations |
Tresiba, Toujeo, Lantus, Basaglar |
Compete for treatment budget and physician attention |
| Insulin pumps |
Tandem, Insulet, Medtronic |
Offer automated or semi-automated insulin delivery |
| Continuous glucose monitoring |
Dexcom, Abbott FreeStyle Libre |
Strengthen injectable and pump-based treatment ecosystems |
| GLP-1 and incretin therapies |
Ozempic, Mounjaro, Trulicity, Wegovy |
Delay or reduce insulin initiation in some type 2 patients |
| Generic and biosimilar insulin |
Multiple manufacturers |
Increase price pressure on injectable alternatives |
Afrezza’s differentiation is convenience and delivery route. Its disadvantage is that the product requires a separate basal-insulin strategy for many patients, making the overall regimen more complex than an oral, injectable, or pump-based alternative.
What is Afrezza’s financial trajectory?
MannKind’s reported revenue has expanded materially since the company regained control of Afrezza commercialization and developed its broader Technosphere manufacturing business.
Public company filings show that MannKind’s total revenue increased from approximately $143 million in 2022 to approximately $192 million in 2023.[2] The growth reflected a combination of Afrezza sales, manufacturing revenue, collaboration revenue, and other platform-related income.
Afrezza-specific revenue is not equivalent to total MannKind revenue. The company’s financial trajectory increasingly reflects its manufacturing and collaboration business, including revenue associated with United Therapeutics’ Tyvaso DPI program.
| Financial driver |
Effect on MannKind |
| Afrezza product sales |
Recurring commercial revenue and brand value |
| Technosphere manufacturing |
Higher-volume contract and collaboration revenue |
| United Therapeutics relationship |
Diversifies revenue beyond Afrezza |
| Research and development |
Supports new inhaled products but consumes cash |
| Commercial infrastructure |
Raises operating costs before prescription growth |
| Reimbursement and gross-to-net discounts |
Limits realized Afrezza revenue |
Afrezza is therefore best assessed as a strategic product within a platform company rather than as MannKind’s sole revenue source.
Is Afrezza profitable for MannKind?
Afrezza’s profitability depends on prescription growth, pricing, manufacturing scale, patient acquisition costs, and reimbursement. MannKind has historically reported operating losses while investing in commercialization, research, development, and manufacturing capacity.[2]
The product has better economic potential when:
- a patient remains on therapy for an extended period;
- insurance coverage reduces out-of-pocket cost;
- MannKind converts patients without excessive promotional spending;
- cartridge production operates at scale; and
- Afrezza sales grow faster than corporate expenses.
The financial leverage is meaningful because MannKind controls the product and its inhalation technology in the United States. However, Afrezza cannot support strong margins if the company must rely heavily on copay assistance, free-trial programs, or high-touch patient education.
What are the key market dynamics affecting Afrezza sales?
Physician adoption is the primary bottleneck
Afrezza requires physicians to understand dose conversion, pulmonary restrictions, and patient selection. Injectable insulin is familiar, widely stocked, and supported by extensive clinical experience. That entrenched workflow limits switching even when patients prefer inhaled delivery.
MannKind’s commercial opportunity is strongest among endocrinologists, diabetes educators, and patients who actively object to injections. Primary-care adoption is more difficult because Afrezza requires additional education and pulmonary screening.
Reimbursement determines patient conversion
Afrezza competes against low-cost and highly familiar injectable insulin products. Commercial insurers may cover the product, but formulary placement, prior authorization, deductibles, and copay levels can prevent prescriptions from becoming sustained use.
The product’s economic model improves when MannKind secures preferred coverage or uses targeted access programs. It weakens when patients face high out-of-pocket costs and abandon therapy after initial use.
The GLP-1 market changes the insulin funnel
GLP-1 receptor agonists and dual incretin therapies have changed the treatment sequence for type 2 diabetes. Many patients now receive incretin-based therapy before insulin. This can reduce the number of newly diagnosed patients entering the prandial-insulin market.
At the same time, patients who eventually require insulin may be more treatment-resistant and more interested in a needle-free option. The net impact depends on whether Afrezza can reach these patients before they become established on injectable insulin or pump therapy.
Pulmonary restrictions narrow the eligible population
The FDA label carries a boxed warning for acute bronchospasm. Afrezza is contraindicated in patients with chronic lung disease such as asthma or chronic obstructive pulmonary disease and is not recommended for people who smoke or recently stopped smoking.[1]
These restrictions remove part of the diabetes population and add an assessment step before treatment. Pulmonary testing also creates a practical burden for prescribers and patients.
What is Afrezza’s FDA regulatory status?
Afrezza remains an FDA-approved inhaled insulin product for adults with diabetes. Its approval is based on the NDA pathway, not the biosimilar pathway used for reference biologics under the Public Health Service Act.
The key regulatory limitations are:
- it is not approved for treatment of diabetic ketoacidosis;
- it is not a substitute for basal insulin;
- it is contraindicated in chronic lung disease;
- lung-function testing is required before treatment and periodically thereafter;
- smoking and recent smoking affect suitability;
- hypoglycemia remains a central insulin-related risk.[1]
Afrezza’s regulatory status is stable, but its label restrictions affect market size and commercial execution.
When does Afrezza lose exclusivity?
Afrezza’s principal FDA regulatory exclusivity periods have expired. The product was approved in 2014, and any original new-product exclusivity did not create a current barrier to follow-on competition.
Patent protection and regulatory exclusivity are separate. A patent can remain enforceable after FDA exclusivity ends, while a follow-on applicant may challenge patents through a Paragraph IV certification.
Because Afrezza is an inhaled formulation with a specialized device and pharmacokinetic profile, a follow-on product would face technical and regulatory hurdles beyond simply reproducing injectable human insulin. A potential competitor would need to address:
- powder particle engineering;
- insulin stability;
- inhaler performance;
- emitted dose and aerodynamic particle size;
- pulmonary deposition;
- systemic exposure;
- clinical comparability; and
- device and cartridge compatibility.
What patent protection covers Afrezza?
Afrezza’s intellectual-property protection is concentrated in several layers:
- the Technosphere carrier platform;
- insulin-particle composition;
- dry-powder formulations;
- inhaler and cartridge systems;
- dose delivery and manufacturing processes; and
- method-of-use claims involving pulmonary insulin delivery.
Patent protection does not automatically prevent competition across all these categories. The commercial strength of the estate depends on claim scope, expiration dates, terminal disclaimers, patent-term adjustment, Orange Book listings, and whether a challenger can design around the relevant claims.
Afrezza’s strongest practical barrier is likely the combined formulation-device-manufacturing package rather than a single composition patent. This raises development costs for competitors, but it does not eliminate the possibility of a 505(b)(2) or other follow-on strategy.
What is the Orange Book status of Afrezza?
Afrezza is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under NDA 022472.[3]
Orange Book analysis should distinguish:
- patents listed against the approved drug;
- patents covering the inhaler or delivery system;
- patents covering the active ingredient or formulation;
- patents with remaining enforceable term; and
- patents vulnerable to Paragraph IV challenge.
A generic applicant that submits an ANDA and certifies that listed patents are invalid, unenforceable, or will not be infringed could trigger patent litigation. The commercial complexity of Afrezza makes a conventional ANDA pathway less straightforward than the pathway for a tablet or injectable solution.
Which companies are challenging Afrezza?
There is no widely established commercial generic or biosimilar competitor to Afrezza comparable to the follow-on competition seen in injectable insulin.
The likely competitive threat is not an immediate branded challenger. It is a future inhaled-insulin or inhalable-peptide product developed through a 505(b)(2), ANDA, or other abbreviated regulatory strategy.
Potential challengers would need to overcome:
- device development;
- pulmonary safety requirements;
- clinical bridging;
- manufacturing scale-up;
- physician education;
- payer acceptance; and
- patent litigation risk.
Afrezza is not interchangeable with a biosimilar insulin under the usual BPCIA framework. It is a drug product approved through an NDA, and any follow-on pathway would depend on the specific product design and FDA determination.
What licensing deals affect Afrezza and MannKind?
Afrezza was initially commercialized through a partnership with Sanofi, but Sanofi terminated its agreement in 2016 after weak uptake and commercial performance. MannKind then resumed control of U.S. commercialization.[4]
The most important later commercial development was MannKind’s broader partnership with United Therapeutics around Technosphere-based pulmonary products, including Tyvaso DPI. That relationship expanded MannKind’s revenue base and validated its inhalation manufacturing capabilities, even though it is not an Afrezza licensing deal.
The strategic consequence is significant: MannKind can use commercial and manufacturing infrastructure developed for partner products to support its own inhaled insulin business. The company also becomes less dependent on Afrezza prescription growth alone.
What generic launch risks exist for Afrezza?
A generic or follow-on launch would face a high technical barrier, but the risk is not zero.
| Risk factor |
Impact |
| Device complexity |
Increases development and regulatory cost |
| Formulation patents |
Can delay or complicate launch |
| Pulmonary safety |
Requires specialized clinical evidence |
| Low current market size |
May reduce challenger incentive |
| Limited physician adoption |
Reduces expected commercial return |
| Existing insulin competition |
Makes price-based entry difficult |
| 505(b)(2) uncertainty |
Creates regulatory pathway risk |
The most plausible competitive event would be a differentiated inhaled insulin or inhaled peptide product rather than a simple low-cost copy. A challenger would need a sufficient commercial market to justify the expense of respiratory-device development and clinical testing.
How strong is the Afrezza commercial position?
Afrezza has a differentiated product with a weak-to-moderate commercial position.
Its strengths are:
- needle-free mealtime insulin delivery;
- rapid absorption;
- control of a specialized delivery platform;
- limited direct competition;
- potential appeal to injection-averse patients; and
- the ability to benefit from MannKind’s broader inhalation infrastructure.
Its weaknesses are:
- limited eligible population;
- pulmonary testing requirements;
- dose-conversion complexity;
- dependence on reimbursement;
- need for basal insulin in many patients;
- competition from highly established injectable products; and
- limited evidence of mass-market adoption.
The product’s patent and manufacturing barriers are stronger than its demand-side barriers. In other words, competitors may find Afrezza difficult to reproduce, but MannKind still must persuade physicians, payers, and patients to use it.
What is the outlook for Afrezza revenue?
The base-case commercial outlook is gradual growth rather than rapid displacement of injectable insulin.
Revenue growth would likely depend on four measurable indicators:
- prescription growth among insulin-using adults;
- improved commercial formulary access;
- lower patient abandonment after sampling;
- increasing contribution from endocrinology and diabetes-specialist channels.
Afrezza revenue could grow faster if MannKind expands coverage and demonstrates better persistence among injection-averse patients. Growth would remain constrained if the product stays concentrated in a small specialist population.
MannKind’s overall financial trajectory is more diversified than Afrezza’s product trajectory. A successful Technosphere partnership can produce corporate revenue growth even if Afrezza remains a niche therapy. Conversely, strong Afrezza prescription growth would improve the value of MannKind’s proprietary platform and provide a higher-margin branded asset.
Key Takeaways
- Afrezza is an FDA-approved inhaled human insulin product marketed by MannKind.
- Its primary commercial advantage is needle-free mealtime delivery.
- Its main barriers are pulmonary restrictions, dose-conversion complexity, reimbursement, and competition from established injectable insulin.
- MannKind’s total revenue increased substantially through 2023, but corporate growth increasingly reflects Technosphere manufacturing and collaboration revenue rather than Afrezza alone.
- Afrezza’s original regulatory exclusivity has expired, while formulation, device, manufacturing, and platform patents remain relevant to follow-on competition.
- No major commercial generic or biosimilar competitor has displaced Afrezza.
- The product has a defensible technical position but a limited mass-market profile.
- The strongest financial upside comes from combining Afrezza prescription growth with MannKind’s external Technosphere manufacturing business.
FAQs
Is Afrezza a biologic or a generic drug?
Afrezza contains recombinant human insulin, a biologically derived active ingredient, but it was approved as an NDA drug product. It is not an interchangeable biosimilar under the standard BPCIA framework.
Can Afrezza replace insulin injections entirely?
No. Afrezza is a mealtime insulin. Many patients with type 1 diabetes and some patients with type 2 diabetes still require separate basal insulin.
Why did Sanofi stop selling Afrezza?
Sanofi ended its commercialization agreement in 2016 after Afrezza generated weak uptake and did not meet commercial expectations. MannKind regained control of U.S. commercialization.
Does Afrezza have a direct inhaled-insulin competitor?
No major marketed product currently competes directly with Afrezza as an inhaled mealtime insulin. Its practical competitors are injectable rapid-acting insulin, pumps, and alternative diabetes therapies.
What would increase Afrezza’s valuation most?
The largest valuation drivers would be sustained prescription growth, improved insurance coverage, evidence of long-term patient persistence, and continued expansion of MannKind’s Technosphere manufacturing partnerships.
References
- U.S. Food and Drug Administration. (2023). Afrezza prescribing information. https://www.accessdata.fda.gov
- MannKind Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- Sanofi. (2016). Sanofi and MannKind terminate Afrezza collaboration agreement. Company release.
